关键词: 阿美替尼, 肌酸激酶, 肺腺癌, 表皮生长因子受体-酪氨酸激酶抑制剂

Abstract: Objective Exploring the characteristics of abnormal elevation of serum creatine kinase （CK）induced by the novel three representative epidermal growth factor receptor tyrosine kinase inhibitors （EGFR-TKIs） aumolertinib， its relationship with dosage， related serological changes，and its impact on treatment decision-making.MethodsThe clinical manifestations， imaging， and pathological features of a patient with lung adenocarcinoma treated with a routine dose of aumolertinib were analyzed，and the literature was reviewed. ResultsIn a 59-year-old female patient with lung adenocarcinoma and EGFR21 exon L858R mutation，CK increased to a peak of 760 U/L（CTCAE grade 3 or above）on 167 days after aumolertinib 110 mg/d treatment，and CK decreased to the normal range on 30 days after withdrawal. During this period，there were no symptoms such as muscle pain，and no evidence of cardiac toxicity or myositis was found in serological and imaging examinations. After aumolertinib was reduced by 110 mg weekly，CK stabilized in the CTCAE level 1 range. ConclusionAsymptomatic elevation of CK may occur during treatment with aumolertinib. The long-term effects of sustained CK elevation on cardiovascular function in patients and the intervention strategies for CK elevation are still uncertain. It is recommended to closely observe clinical symptoms such as muscle pain and monitor serum CK levels during the treatment with aumolertinib.

Key words: aumolertinib, creatine kinase, lung adenocarcinoma, EGFR-TKIs